Skip to main content
Chinese Journal of Reparative and Reconstructive Surgery logoLink to Chinese Journal of Reparative and Reconstructive Surgery
. 2022 Dec;36(12):1549–1557. [Article in Chinese] doi: 10.7507/1002-1892.202209015

肌肉减少症和骨关节炎相关性研究进展

Research progress on the correlation between sarcopenia and osteoarthritis

Hongjun PENG 1, Yi ZENG 1,*
PMCID: PMC9763072  PMID: 36545865

Abstract

Objective

To review the research progress on the correlation between sarcopenia and osteoarthritis (OA).

Methods

The basic and clinical studies at home and abroad in recent years on sarcopenia and OA were extensively reviewed. The correlation between sarcopenia and OA was analyzed and summarized from five aspects: epidemiological status, risk factors, pathogenesis, clinical treatments, and the impact on joint arthroplasty.

Results

Sarcopenia and OA are common diseases in the elderly with high prevalence and can increase the ill risk of each other. They share a set of risk factors, and show negative interactive and influence on pathogenesis and clinical treatments, thus participating in each other’s disease process and reducing the treatment benefits. Clinical studies show that sarcopenia can affect the rehabilitation effect and increase the risk of postoperative complications after total joint arthroplasty in many ways.

Conclusion

Current research results show that sarcopenia and OA are related and can be mutually affected in the above 5 aspects, but more studies are needed to further clarify the relationship between them, so as to provide more theoretical basis for the understanding, prevention, diagnosis, and treatments of the two diseases.

Keywords: Sarcopenia, osteoarthritis, correlation, epidemiology, pathogenesis, clinical treatments, total joint arthroplasty


肌肉减少症简称“肌少症”,是一种全身性、渐进性肌肉质量损失和力量下降的老年综合征,与跌倒、骨折和骨密度降低等因素密切相关[1]。骨关节炎(osteoarthritis,OA)是中老年最常见的慢性退行性关节病,以关节疼痛和功能障碍为主要特征,被认为是“不死的癌症”。这两种疾病的发病群体以老年人为主,具有较高的患病率、致残率和死亡率[2-4]。近年来,随着全球老龄化程度加剧,肌少症和OA的多发共存现象越来越普遍。因此,探讨和阐明这两种肌肉骨骼系统疾病的相关性具有积极意义。目前关于肌少症和OA相关性的研究尚在探索阶段,但也初步表明两者的紧密关系。本文将对两者相关性研究进展综述如下。

1. 肌少症和OA的诊断标准

自1998年Richard等首次提出肌少症的诊断标准后,欧洲老年肌少症工作组(EWGSOP)、欧洲老年肌少症工作组2(EWGSOP2)、亚洲肌少症工作组2014(AWGS2014)、亚洲肌少症工作组2019(AWGS2019)、国际肌少症工作组(IWGS)和美国国立卫生研究基金会(FNIH)等组织相继提出各自诊断标准,见表1图1将以目前引用最广泛的EWGSOP2和AWGS2019诊断标准为例,对肌少症诊断流程进行介绍和区分。

表 1.

Diagnostic paraments and critical points for sarcopenia

肌少症诊断参数和临界点

诊断标准
Diagnostic
standard
肌肉质量
测定方法
Muscle mass
measurement method
肌肉质量
Muscle mass
肌肉力量
Muscle strength
机体功能
Physical performance
注:DXA:双能X线吸收法;BIA:生物电阻抗分析法;ASM 或ALM:四肢骨骼肌量;SPPB:简易体能状况量表
Note: DXA: Dual-energy X-ray absorptiometry; BIA: Bioelectrical impedance analysis; ASM/ALM: Appendicular skeletal muscle mass/Appendicular lean mass; SPPB: Short physical performance battery
AWGS2014[5] DXA
BIA
ASM/身高2:男性≤7.00 kg/m2,女性≤5.40 kg/m2
ASM/身高2:男性≤7.00 kg/m2,女性≤5.70 kg/m2
握力:男性<26 kg,
女性<18 kg
步速≤0.8 m/s
AWGS2019[6] 人体测量
DXA

BIA
小腿围:男性<34 cm,女性<33 cm
ASM/身高2:男性≤7.00 kg/m2,女性≤5.40 kg/m2

ASM/身高2:男性≤7.00 kg/m2,女性≤5.70 kg/m2
握力:男性<28 kg,
女性<18 kg
步速≤1.0 m/s
连续5次起坐时间≥12 s
SPPB≤9分
EWGSOP[7] DXA

BIA
ASM/身高2:男性<7.26 kg/m2,女性<5.50 kg/m2
ASM/身高2:男性<8.87 kg/m2,女性<6.42 kg/m2
握力:男性<30 kg,
女性<20 kg
步速≤0.8 m/s
EWGSOP2[1] DXA或BIA ASM/身高2:男性<7.00 kg/m2,女性<5.50 kg/m2 握力:男性<27 kg,
女性<16 kg
步速≤0.8 m/s
SPPB≤8分
连续5次起坐时间>15 s
IWGS[8] DXA ALM/身高2:男性≤7.23 kg/m2,女性≤5.67 kg/m2 步速≤1.0 m/s
FNIH[9] DXA ASM/身体质量指数:男性<0.789 kg/(kg·m2),
女性<0.512 kg/(kg·m2
ALM:男性<19.75 kg,女性<15.02 kg
握力:男性<26 kg,
女性<16 kg
步速≤0.8 m/s

图 1.

The diagnosis process for sarcopenia

肌少症的诊断流程

SARC-F:S(肌肉力量)、A(辅助行走)、R(座椅起立)、C(爬楼梯)、F(跌倒次数) SARC-CalF:S(肌肉力量)、A(辅助行走)、R(座椅起立)、C(爬楼梯)、Cal(小腿围)、F(跌倒次数) DXA:双能X线吸收法 BIA:生物电阻抗分析法 SPPB:简易体能状况量表 TUG:起立行走测试 a. EWGSOP2诊断流程;b. AWGS2019诊断流程

SARC-F: S (Strength), A (Assistance in walking), R (Rising from a chair), C (Climbing stairs), F (Falls) SARC-CalF: S (Strength), A (Assistance in walking), R (Rising from a chair), C (Climbing stairs), Cal (Calf circumference), F (Falls) DXA: Dual-energy X-ray absorptiometry BIA: Bioelectrical impedance analysis SPPB: Short physical performance battery TUG: The timed up and go a. EWGSOP2 diagnosis process; b. AWGS2019 diagnosis process

图 1

OA的临床诊断主要依靠临床表现和影像学检查。《中国骨关节炎诊疗指南(2021年版)》中膝关节和髋关节OA的诊断标准[10]表23

表 2.

Diagnostic criteria of hip OA

髋关节OA的诊断标准

OA诊断相关临床问题
Clinical problems related to
OA diagnosis
参数或指标
Parameters or indices
证据等级
Level of evidences
高危人群 ① 年龄≥40岁、女性、肥胖或超重、创伤史
② 髋臼发育不良、股骨颈凸轮样畸形、长期从事负重劳动等特殊职业或家族中有OA
患者等危险因素
B
C
临床表现 关节疼痛和关节活动受限
步态异常(中重度髋OA)
C
影像学检查(首选X线片) ① 正位骨盆X线片:关节间隙变窄,髋臼边缘骨赘形成、软骨下硬化和/或囊性变,股
骨头变形,合并髋臼发育不良者可见浅髋臼、股骨头外上方半脱位或脱位等
② 双下肢全长X线片:下肢力线异常
B

鉴别诊断 与其他引起关节疼痛和功能障碍的疾病相鉴别,包括自身免疫性疾病关节炎、感染性
关节炎、痛风、假性痛风

表 3.

Diagnostic criteria of knee OA

膝关节OA的诊断标准

OA诊断相关临床问题
Clinical problems related to
OA diagnosis
参数或指标
Parameters or indices
证据等级
Level of evidences
高危人群 ① 年龄≥40岁、女性、肥胖或超重、创伤史
② 膝关节周围肌肉萎缩、长期从事负重等特殊职业、家族中有OA患者、位于
高风险地区或肠道菌群紊乱等危险因素
B
C
临床表现 关节疼痛和关节活动受限、压痛和关节畸形
关节肿大、骨擦音(感)、步态异常(中重度膝OA)
C
影像学检查(首选X线片) ① 正位X线片:关节间隙变窄、骨赘形成、骨质硬化或囊性变、关节畸形及
髌骨脱位或半脱位等
② 双下肢全长X线片:下肢力线异常
B
鉴别诊断 与其他引起关节疼痛和功能障碍的疾病相鉴别,包括自身免疫性疾病关节炎、
感染性关节炎、痛风、假性痛风

2. 肌少症和OA的流行病学现状

2.1. 全球和我国肌少症的流行病学现状

目前,全球约有5 000万人罹患肌少症,预计2050年将达5亿人[711]。Petermann-Rocha等[2]归纳151项研究得出,全球60岁以上老年人肌少症患病率为10.00%~27.00%,重度肌少症患病率为2.00%~9.00%。全球区域性患病率差异明显,印度肌少症患病率为26.60%~39.10%[12],而加拿大仅为1.48%~6.16%[13]。Shafiee等[14]采用统一标准分析后显示,同亚洲人相比,非亚洲人的肌少症患病率较高,但男女性总体估计患病率均为10.00%,未见明显性别差异。肌少症患病率随年龄增长而增加,80岁以上老人患病率高达50.00%[15]。不同种族间的患病率有较大差异,如苏里南男性患病率比土耳其男性高31.50%[16]

我国总体肌少症患病率约为16.00%,重度肌少症患病率约为8.00%,女性患病率略高于男性[17-18]。在流行病学分布上,最突出的是年龄和人群类型的差异。肌少症患病率与增龄显著相关,60岁以上人群的患病率为2.61%~9.72%,而80岁以上人群达18.52%~55.56%[19]。我国社区居民肌少症患病率波动较大,最高可达57.10%,但无明显性别差异[20-21]。同社区患病率相比,住院患者和养老院居住人群的肌少症患病率成倍增加[22]。合并症(如糖尿病)人群的肌少症患病率也明显高于普通人[23]。我国西部地区的患病率高于东部地区[1924],农村地区高于城市地区[18]。一项多民族间肌少症调研显示,不同民族的肌少症患病率差距较大,彝族患病率最高(34.70%),羌族最低(11.80%)[25]。综上,我国各层面的肌少症患病率水平较高,且随着老龄化加剧和慢性病患病人群增多,肌少症患病率将呈进一步上升趋势,医务人员需对此重视和采取措施加以控制和管理。

2.2. 全球和我国OA的流行病学现状

目前全球约2.4亿人患症状性OA,女性患病率约为男性的1.80倍[26]。OA通常被认为是老年相关性疾病,但OA的发病人群正趋向年轻化,65岁以下患病人群比例明显增加[27]。OA在区域分布上有明显的国际性差异,变化率最高和最低的地区相差3 245.6/10万,即使最低地区也达到了2 678.3/10万[28]。因此,多数国家的医疗负担正在加重。

目前,我国OA患病人数超过1.50亿,每年发病人数超过千万,女性多于男性。随着我国老龄化程度加剧,OA患病率会进一步增加,性别差异更大。从人群分布上[29-30],OA在患病年龄上有明显的“老年病”特征,40岁以上人群的患病率显著增加,70岁后趋于稳定,女性患病率明显高于男性。从地区分布上,发达地区的居住人群患病率较低,西南和西北地区患病率最高,几乎是华北和东部地区的2倍[30]。农村膝OA患病率高于城市,而城市髋OA高于农村。此外,同欧美人相比,中国女性OA患病率高于白人女性,但男性无差异[31]。中国男女性OA流行病学调查结果见图2,数据来源于2019年全球疾病负担数据库(GBD2019)。

图 2.

Results of an epidemiological survey of OA in Chinese men and women

中国男女性OA流行病学调查结果

a. 2014年—2019年中国男女性OA发病人数和患病人数; b. 2019年中国男女不同年龄段OA发病率和患病率

a. Number of onsets and cases among men and women with OA in China between 2014 and 2019; b. Incidence and prevalence of OA in Chinese men and women at different age levels in 2019

图 2

2.3. 肌少症与OA的流行病学相关性

肌少症和OA多发共存的重要原因之一就是两者会增加彼此发病风险。首先,肌少症是增加OA发病率的危险因素。Jin等[32]通过对照研究发现,肌少症肥胖女性的膝OA发生风险是非肌少症肥胖女性的2.43倍,且肌少症肥胖女性几乎是男性的10倍。这种显著的性别差异可能解释女性OA患病率高于男性。股四头肌肌力下降是膝OA发生的重要因素,因此下肢低肌肉质量与膝OA患病率成负相关关系[33],且这种相关性与年龄和性别无关。此外,OA也会明显增加肌少症的患病风险,德国FORMoSA的一项研究显示,在70岁及以上老年女性中,髋(膝)OA个体的肌少症患病率比非OA个体高出1.60倍[34]。另外一项横断面研究也表明,OA患者合并肌少症的比例高达41.70%,显著高于非OA患者[35]

3. 肌少症与OA的共同危险因素

3.1. 肥胖

脂肪和肌肉的质量比值随年龄增长而逐渐升高。目前,已有研究表明肌少症的发生和发展与体内脂肪增加相关。神经-肌肉接头病变是肌少症的重要病因之一,一项动物实验表明,高脂肪饲喂小鼠发生肥胖后,其神经-肌肉接头继发各种与肥胖相关的结构变化,包括突触区受损、乙酰胆碱表达和分布异常,且肥胖持续时间越长,这种改变越严重[36]。肌周和肌细胞间的脂肪组织与引发肌肉损失的慢性炎症密切相关[37]。Abete等[38]研究表明,通过饮食和身体活动降低脂肪/肌肉质量比,能调节人体的系统炎症反应,从而减少这一因素参与肌少症的发生、发展过程。肥胖往往会增加体质量,增强的关节负荷导致软骨磨损和炎症反应,特别是免疫反应失调参与肥胖诱导OA的发生、发展[39],这也是近年研究关注焦点。

3.2. 糖尿病

胰岛素抵抗会抑制肌细胞利用葡萄糖的关键靶点和降低代谢相关蛋白的表达,通过肌肉蛋白稳态失衡和增加肌肉抑制素等途径减少肌肉量[40-41]。这种失效的胰岛素信号传导会增强胰岛素抵抗,使肌肉损失进入恶性循环。近年来研究发现胰岛素抵抗与OA的发生、发展相关,通过介导软骨细胞代谢紊乱、增强炎症因子表达和抑制自噬来刺激OA发展。Ribeiro等[42]研究发现,同健康和非糖尿病OA患者相比,糖尿病OA患者软骨细胞表达微管相关蛋白1轻链3降低,而表达前核糖体蛋白S6激酶增加,两者的表达变化通过抑制软骨细胞自噬来促进软骨退变和损伤。Qiao等[43]研究表明高胰岛素浓度通过系列增强滑膜炎症的途径来加速OA进程。另外,OA合并糖尿病还会增加肌肉损失,Zaharia等[44]研究发现,OA合并糖尿病患者比单纯OA患者的大腿部肌肉功能评分降低了60%,导致关节活动性更差。

3.3. 维生素D缺乏

维生素D对肌肉和软骨都具有重要作用,能刺激肌纤维增殖和分化,维持和提高肌肉力量及机体性能,因此维生素D缺乏增加了肌少症发生风险,且缺乏水平越高,肌少症越严重[45]。维生素D还能保护软骨,通过诱导软骨细胞产生一氧化氮来减少软骨破坏和延缓OA进展,Veronese等[46]研究表明OA患者口服较高剂量的维生素D(250 IU)能有效改善软骨结构和保护软骨。

3.4. 年龄

衰老是所有组织和器官发生病理变化的最常见形式,肌少症和OA的发病也不例外,伴随它们发生、发展的关键因素之一就是炎性衰老,通过慢性炎症反应损伤肌肉和软骨并降低其修复能力[47],从而诱发两者发病。其次,在衰老过程中,肌卫星细胞和关节软骨细胞的增殖、分化能力降低会使组织进入退化状态[48],加速肌少症和OA进展。

4. 肌少症与OA发病机制的相关性

4.1. 肌力下降和OA

肌力下降是肌少症的主要特征,被视为OA发病的独立危险因素。肌力下降可改变机械应力、降低关节稳定性,加速软骨退变和软骨下骨异常改变。Xu等[49]的大鼠肌萎缩模型显示,与空白对照组相比,肌力下降组更易出现OA特征性变化,软骨表面磨损且厚度变薄,骨小梁呈板状转变,证实了肌力下降可诱发OA。肌力下降对OA疼痛有显著影响[50],而疼痛是OA主要临床症状,表明肌力下降是关节损伤和疼痛进一步发展的重要危险因素。

下肢肌力下降普遍存在于不同等级的膝(髋)OA患者中。因OA的疼痛或肌肉神经源性激活迫使患者处于久坐状态,从而造成肌肉萎缩。Steidle-Kloc等[51]的研究结果支持该观点,他们认为对侧膝关节疼痛能通过中枢神经抑制降低无疼痛关节的肌肉力量。而OA患者肌力下降的直接证据是肌纤维结构和比例的改变,Noehren等[52]在膝OA患者中发现,股四头肌肌力下降与其混合Ⅱ型肌纤维增多及Ⅰ/Ⅱ型肌纤维比例降低显著相关,且伴随骨骼肌外基质和纤维化程度明显增加,这极大地降低了肌肉性能。

4.2. 促炎症反应

炎症在联系肌少症和OA发病相关性上起“桥梁”作用。由于促炎细胞因子增多导致炎症系统失衡,诱导肌肉和关节软骨蛋白合成和分解失调,最终诱发滑膜炎症而导致肌肉损失和软骨破坏。Silva等[53]在大鼠模型中发现,膝OA侧腓肠肌可表达更多IL-1β,而横截面积减少10%(肌生长抑制素增多,肌肉生成素减少),表明炎症信号与腓肠肌萎缩间具有相关性,且这种相关性与OA相关。膝OA的炎症特性还会导致神经改变,进一步引起肌肉萎缩。Cunha等[54]在大鼠模型中发现,与膝OA相关的股四头肌神经-肌肉接头发生重构,并进一步诱发调节乙酰胆碱受体的萎缩蛋白MuRF-1增多,加速肌肉萎缩和肌力下降。

肌少症可降低关节稳定性,进而诱发炎症性关节内环境,这种内环境的改变会加速OA疾病进程。Egloff等[55]在兔模型中发现,关节不稳的滑膜和软骨中有大量炎症细胞浸润,IL-1/6和TGF-β等细胞因子显著增加,且软骨明显退化,提示慢性肌无力通过诱发炎症反应参与OA病理过程。上述结果意味着细胞因子作为媒介将肌少症和OA的发病联系起来,导致两者相互影响。

4.3. 鸢尾素

鸢尾素是骨骼肌合成后释放入血的生物活性蛋白,经不同分泌途径发挥生物学效应,影响骨骼肌和关节内组织的代谢和信号转导并产生正性调节作用。骨骼肌是鸢尾素的主要储存库,很大程度上决定着循环鸢尾素浓度。研究显示,肌少症患者血清鸢尾素水平较健康人降低[56],且血清和滑液中鸢尾素浓度的降低与诱发OA程度具有关联[57]。Li等[58]发现,鸢尾素基因敲除小鼠会发生严重OA,而鸢尾素基因敲入或关节内注入鸢尾素的OA小鼠会抑制OA的进展。鸢尾素可通过抑制p38/AKT/NF-κB信号通路刺激软骨细胞增殖、抑制软骨基质降解和促炎反应,从而实现对软骨的保护作用[59]

骨骼肌的鸢尾素表达能力与身体活动密切相关,症状性OA患者因身体活动量低可导致血液循环和滑液中的鸢尾素浓度降低[57],表明OA骨骼肌的鸢尾素表达会明显降低。若鸢尾素以自分泌方式作用于肌肉的量减少时,可诱发肌肉萎缩,从而导致肌少症,其机制为一方面通过加速线粒体含量下降和减少肌纤维数量来降低其成肌潜能,另一方面通过降低对肌生成抑制素的负性调控作用导致肌肉损失[60]。此外,循环鸢尾素浓度降低还会导致骨质疏松,加重骨骼肌损失和力量下降[61]

5. 肌少症与OA在临床治疗中的相关性

肌少症和OA在物理和病理表现方面有许多相似性,且从传统的机械相互作用到内分泌的生化信号均有相关性。因此,探讨它们共同的治疗措施,或一者的治疗效果受另一者影响的情况,是目前临床治疗的主要研究方向。这些研究表明两者在临床治疗中具有相关性,但证据仍十分有限,有待进一步突破。

肌肉质量和力量是临床治疗中连接肌少症和OA的重要枢纽。Liao等[62]的研究结果显示,伴有肌少症的OA患者补充蛋白的同时结合阻力训练,不仅在肌肉质量和性能上得到有效提升,还能借此增强关节稳定性和机体平衡性,从而减轻OA疼痛和活动障碍。肌力下降导致的肌力失衡是全关节置换术(total joint arthroplasty,TJA) 术前的特征,Vodička等[63]通过评估人工全髋关节置换术(total hip arthroplasty,THA)患者和健康老年人的下肢肌力发现,THA患者患肢的伸肌肌力不但明显减弱,而且伴随双侧伸肌肌力严重失衡。他们经过统计分析后发现,双侧伸肌肌力失衡的严重程度与THA显著相关,意味着双侧伸肌肌力失衡可用于预测患者是否需要接受THA治疗。

OA的治疗措施多样且日趋成熟,但不乏因肌肉损失而降低OA治疗效果的报道。在一项OA的保守治疗研究中,Toda等[64]发现使用距下系带鞋垫能改善膝OA症状,但受下肢肌肉损失程度的影响,与初始OA症状评估相比,距下系带鞋垫组中下肢肌肉质量/体质量比<18%的患者会有更严重的膝关节内翻畸形和OA症状。这可能是因为关节周围肌肉质量损失导致矫形鞋垫无法矫正股骨-胫骨角和维持膝关节平衡,从而丧失对关节的保护作用,甚至加速OA进展。

TJA对提升OA患者肌肉力量和性能具有积极作用,从而有益于关节活动恢复。Wang等[65]随访人工全膝关节置换术(total knee arthroplasty,TKA)患者术后肌力变化发现,OA患者股四头肌和腘绳肌的肌力在术后均较术前增强,且在术后1、3、6个月逐渐改善至接近健侧肌力水平,膝关节活动度也明显增大。Cavanellas等[66]也评估了膝OA患者股四头肌和腘绳肌的强度,发现术后强度增加能改善膝关节疾病和术后功能恢复。

目前,肌少症治疗的有效措施相对缺乏,已有研究显示肌少症和OA在治疗上具有关联。在一项探究联合运动对肌少症和OA影响的研究中,Park等[67]对肌少症组和肌少症合并OA组干预后发现,两组患者的大腿横截面积均会增加,但肌少症组增加更多;此外,他们还发现肌少症合并OA组的肌肉生长抑制素降低程度更大,同时日常生活活动评分变化更明显,表明运动训练治疗肌少症能改善OA相关症状,但合并OA时也会降低肌少症的治疗效果。

6. 肌少症对终末期OA患者行TJA术后康复的影响

TJA是治疗终末期OA的首选方案,但肌少症会导致TJA术后康复效果质量降低,因此对合并肌少症的TJA患者,在术后康复中应引起足够重视。一项针对90 438例OA患者术后随访发现,合并肌少症患者住院时间更长、90 d内医疗并发症和再手术风险更高,且2年内假体失败率更高[68]。Liao等[69]的临床研究显示肌少症程度越严重,TJA术后机体恢复越差,且随时间延长逐渐降低,这增加了术后跌倒、下肢骨折的风险,极大降低了手术效果。因此,术前评估TJA患者是否合并肌少症非常重要。

肌少症可增加术后假体感染风险。Babu等[70]利用中枢肌少症标志腰大肌-腰椎指数(psoas-lumbar vertebral index,PLVI)分析THA和TKA术后假体感染和非感染患者,发现两者的PLVI存在显著差异,感染患者的PLVI明显更低;多因素logistic回归分析发现,PLVI是术后假体感染的重要预测因子,表明肌少症与术后假体感染有明确相关性。

TJA术后假体周围骨量损失会导致假体早期松动,从而增加翻修可能。Mau-Moeller等[71]通过建立结构方程模型分析OA患者在TKA术后的假体周围骨密度变化,发现股骨远端假体周围骨密度降低与患肢肌肉质量减少直接相关,这表明肌少症能导致TKA术后假体周围骨密度降低,进而导致假体松动和翻修。

7. 小结与展望

肌少症和OA是老年人群的常见疾病,患病率水平与年龄显著相关且受多因素影响。目前的基础研究和临床研究都表明两者具有较强相关性,尤其在发病机制和临床治疗两大关键方面。肌少症和OA是相互影响的骨骼肌肉系统疾病,尽管TJA已是治疗终末期OA的“金标准”,但肌少症仍是降低其治疗获益的重要因素之一。目前肌少症术前管理仍是医护人员的重大挑战,希望加强对两者相关性的认识,通过制定可供参考的诊疗共识对此类患者进行术前筛查、病例发现和干预,以及不良事件发生的评估并采取预防措施,以期减少在治疗过程中的消极影响。

利益冲突 在课题研究和文章撰写过程中不存在利益冲突;课题经费支持没有影响文章观点

作者贡献声明 彭洪俊:综述构思、文献查阅及文章撰写;曾羿:审校并修改论文

Funding Statement

国家自然科学基金青年项目(81601936);四川省科技厅项目(2019YFS0266)

Youth Project of National Natural Science Foundation of China (81601936); Science and Technology Department Project of Sichuan Province (2019YFS0266)

References

  • 1.Cruz-Jentoft AJ, Bahat G, Bauer J, et al Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. doi: 10.1093/ageing/afy169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Petermann-Rocha F, Balntzi V, Gray SR, et al Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022;13(1):86–99. doi: 10.1002/jcsm.12783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Tournadre A, Vial G, Capel F, et al Sarcopenia. Joint Bone Spine. 2019;86(3):309–314. doi: 10.1016/j.jbspin.2018.08.001. [DOI] [PubMed] [Google Scholar]
  • 4.Vina ER, Kwoh CK Epidemiology of osteoarthritis: literature update. Curr Opin Rheumatol. 2018;30(2):160–167. doi: 10.1097/BOR.0000000000000479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Chen LK, Liu LK, Woo J, et al Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014;15(2):95–101. doi: 10.1016/j.jamda.2013.11.025. [DOI] [PubMed] [Google Scholar]
  • 6.Chen LK, Woo J, Assantachai P, et al Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–307. doi: 10.1016/j.jamda.2019.12.012. [DOI] [PubMed] [Google Scholar]
  • 7.Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–423. doi: 10.1093/ageing/afq034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Fielding RA, Vellas B, Evans WJ, et al Sarcopenia: an undiagnosed condition in older adults. Current consensus definition:prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–256. doi: 10.1016/j.jamda.2011.01.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Studenski SA, Peters KW, Alley DE, et al The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69(5):547–558. doi: 10.1093/gerona/glu010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.中华医学会骨科学分会关节外科学组, 中国医师协会骨科医师分会骨关节炎学组, 国家老年疾病临床医学研究中心 (湘雅医院), 等 中国骨关节炎诊疗指南 (2021年版) 中华骨科杂志. 2021;41(18):1291–1314. doi: 10.3760/cma.j.cn121113-20210624-00424. [DOI] [Google Scholar]
  • 11.Hida T, Harada A, Imagama S, et al Managing sarcopenia and its related-fractures to improve quality of life in geriatric populations. Aging Dis. 2014;5(4):226–237. doi: 10.14336/AD.2014.0500226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zengin A, Kulkarni B, Khadilkar AV, et al Prevalence of sarcopenia and relationships between muscle and bone in Indian men and women. Calcif Tissue Int. 2021;109(4):423–433. doi: 10.1007/s00223-021-00860-1. [DOI] [PubMed] [Google Scholar]
  • 13.Purcell SA, MacKenzie M, Barbosa-Silva TG, et al Sarcopenia prevalence using different definitions in older community-dwelling canadians. J Nutr Health Aging. 2020;24(7):783–790. doi: 10.1007/s12603-020-1427-z. [DOI] [PubMed] [Google Scholar]
  • 14.Shafiee G, Keshtkar A, Soltani A, et al Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diabetes Metab Disord. 2017;16:21. doi: 10.1186/s40200-017-0302-x. doi: 10.1186/s40200-017-0302-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Therakomen V, Petchlorlian A, Lakananurak N Prevalence and risk factors of primary sarcopenia in community-dwelling outpatient elderly: a cross-sectional study. Sci Rep. 2020;10(1):19551. doi: 10.1038/s41598-020-75250-y. doi: 10.1038/s41598-020-75250-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Dorhout BG, Overdevest E, Tieland M, et al Sarcopenia and its relation to protein intake across older ethnic populations in the Netherlands: the HELIUS study. Ethn Health. 2022;27(3):705–720. doi: 10.1080/13557858.2020.1814207. [DOI] [PubMed] [Google Scholar]
  • 17.Xin C, Sun X, Lu L, et al Prevalence of sarcopenia in older Chinese adults: a systematic review and meta-analysis. BMJ Open. 2021;11(8):e041879. doi: 10.1136/bmjopen-2020-041879. doi: 10.1136/bmjopen-2020-041879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wu X, Li X, Xu M, et al Sarcopenia prevalence and associated factors among older Chinese population: Findings from the China Health and Retirement Longitudinal Study. PLoS One. 2021;16(3):e0247617. doi: 10.1371/journal.pone.0247617. doi: 10.1371/journal.pone.0247617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Huang J, He F, Gu X, et al Estimation of sarcopenia prevalence in individuals at different ages from Zheijang province in China. Aging (Albany NY) 2021;13(4):6066–6075. doi: 10.18632/aging.202567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.田小丽, 杨蕾, 沈静, 等 乌鲁木齐市米东区社区中老年肌肉减少症患病率及影响因素. 中华骨质疏松和骨矿盐疾病杂志. 2020;13(1):21–26. doi: 10.3969/j.issn.1674-2591.2020.01.004. [DOI] [Google Scholar]
  • 21.Liu X, Hou L, Zhao W, et al The comparison of sarcopenia diagnostic criteria using AWGS 2019 with the other five criteria in west China. Gerontology. 2021;67(4):386–396. doi: 10.1159/000513247. [DOI] [PubMed] [Google Scholar]
  • 22.Chen Z, Li WY, Ho M, et al The prevalence of sarcopenia in Chinese older adults: Meta-analysis and meta-regression. Nutrients. 2021;13(5):1441. doi: 10.3390/nu13051441. doi: 10.3390/nu13051441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Pacifico J, Geerlings MAJ, Reijnierse EM, et al Prevalence of sarcopenia as a comorbid disease: A systematic review and meta-analysis. Exp Gerontol. 2020;131:110801. doi: 10.1016/j.exger.2019.110801. doi: 10.1016/j.exger.2019.110801. [DOI] [PubMed] [Google Scholar]
  • 24.Liu X, Hou L, Xia X, et al Prevalence of sarcopenia in multi ethnics adults and the association with cognitive impairment: findings from West-China health and aging trend study. BMC Geriatr. 2020;20(1):63. doi: 10.1186/s12877-020-1468-5. doi: 10.1186/s12877-020-1468-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Liu X, Hao Q, Hou L, et al Ethnic groups differences in the prevalence of sarcopenia using the AWGS criteria. J Nutr Health Aging. 2020;24(6):665–671. doi: 10.1007/s12603-020-1381-9. [DOI] [PubMed] [Google Scholar]
  • 26.Allen KD, Thoma LM, Golightly YM Epidemiology of osteoarthritis. Osteoarthritis Cartilage. 2022;30(2):184–195. doi: 10.1016/j.joca.2021.04.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Driban JB, Harkey MS, Liu SH, et al Osteoarthritis and aging: Young adults with osteoarthritis. Current Epidemiology Reports. 2020;7(1):9–15. doi: 10.1007/s40471-020-00224-7. [DOI] [Google Scholar]
  • 28.Safiri S, Kolahi AA, Smith E, et al Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis. 2020;79(6):819–828. doi: 10.1136/annrheumdis-2019-216515. [DOI] [PubMed] [Google Scholar]
  • 29.Li D, Li S, Chen Q, et al The prevalence of symptomatic knee osteoarthritis in relation to age, sex, area, region, and body mass index in China: A systematic review and meta-analysis. Front Med (Lausanne) 2020;7:304. doi: 10.3389/fmed.2020.00304. doi: 10.3389/fmed.2020.00304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Tang X, Wang S, Zhan S, et al The prevalence of symptomatic knee osteoarthritis in china: results from the china health and retirement longitudinal study. Arthritis Rheumatol. 2016;68(3):648–653. doi: 10.1002/art.39465. [DOI] [PubMed] [Google Scholar]
  • 31.Callahan LF, Cleveland RJ, Allen KD, et al Racial/ethnic, socioeconomic, and geographic disparities in the epidemiology of knee and hip osteoarthritis. Rheum Dis Clin North Am. 2021;47(1):1–20. doi: 10.1016/j.rdc.2020.09.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Jin WS, Choi EJ, Lee SY, et al Relationships among obesity, sarcopenia, and osteoarthritis in the elderly. J Obes Metab Syndr. 2017;26(1):36–44. doi: 10.7570/jomes.2017.26.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kim SR, Choi KH, Jung GU, et al Associations between fat mass, lean mass, and knee osteoarthritis: The FIFTH Korean National Health and Nutrition Examination Survey (KNHANES V) Calcif Tissue Int. 2016;99(6):598–607. doi: 10.1007/s00223-016-0190-y. [DOI] [PubMed] [Google Scholar]
  • 34.Kemmler W, Teschler M, Goisser S, et al Prevalence of sarcopenia in Germany and the corresponding effect of osteoarthritis in females 70 years and older living in the community: results of the FORMoSA study. Clin Interv Aging. 2015;10:1565–1573. doi: 10.2147/CIA.S89585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Dhannakulsakti P, Roopsawang I, Aree-Ue S Sarcopenia among older adults with knee osteoarthritis: A cross-sectional study of prevalence and its associated factors. Pacific Rim International Journal of Nursing Research. 2022;26(1):121–134. [Google Scholar]
  • 36.Martinez-Pena Y Valenzuela I, Akaaboune M The disassembly of the neuromuscular synapse in high-fat diet-induced obese male mice. Mol Metab. 2020;36:100979. doi: 10.1016/j.molmet.2020.100979. doi: 10.1016/j.molmet.2020.100979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Wu H, Ballantyne CM Skeletal muscle inflammation and insulin resistance in obesity. J Clin Invest. 2017;127(1):43–54. doi: 10.1172/JCI88880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Abete I, Konieczna J, Zulet MA, et al Association of lifestyle factors and inflammation with sarcopenic obesity: data from the PREDIMED-Plus trial. J Cachexia Sarcopenia Muscle. 2019;10(5):974–984. doi: 10.1002/jcsm.12442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Nedunchezhiyan U, Varughese I, Sun AR, et al Obesity, inflammation, and immune system in osteoarthritis. Front Immunol. 2022;13:907750. doi: 10.3389/fimmu.2022.907750. doi: 10.3389/fimmu.2022.907750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Turner MC, Martin NRW, Player DJ, et al Characterising hyperinsulinemia-induced insulin resistance in human skeletal muscle cells. J Mol Endocrinol. 2020;64(3):125–132. doi: 10.1530/JME-19-0169. [DOI] [PubMed] [Google Scholar]
  • 41.Nishikawa H, Asai A, Fukunishi S, et al. Metabolic syndrome and sarcopenia. Nutrients, 2021, 13(10). doi: 10.3390/nu13103519.
  • 42.Ribeiro M, López de Figueroa P, Blanco FJ, et al Insulin decreases autophagy and leads to cartilage degradation. Osteoarthritis Cartilage. 2016;24(4):731–739. doi: 10.1016/j.joca.2015.10.017. [DOI] [PubMed] [Google Scholar]
  • 43.Qiao L, Li Y, Sun S Insulin exacerbates inflammation in fibroblast-like synoviocytes. Inflammation. 2020;43(3):916–936. doi: 10.1007/s10753-020-01178-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Zaharia OP, Pesta DH, Bobrov P, et al Reduced muscle strength is associated with insulin resistance in type 2 diabetes patients with osteoarthritis. J Clin Endocrinol Metab. 2021;106(4):1062–1073. doi: 10.1210/clinem/dgaa912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Hernández-Luis R, Martín-Ponce E, Monereo-Muñoz M, et al Prognostic value of physical function tests and muscle mass in elderly hospitalized patients. A prospective observational study. Geriatr Gerontol Int. 2018;18(1):57–64. doi: 10.1111/ggi.13138. [DOI] [PubMed] [Google Scholar]
  • 46.Veronese N, La Tegola L, Mattera M, et al Vitamin D intake and magnetic resonance parameters for knee osteoarthritis: Data from the osteoarthritis initiative. Calcif Tissue Int. 2018;103(5):522–528. doi: 10.1007/s00223-018-0448-7. [DOI] [PubMed] [Google Scholar]
  • 47.Pan L, Xie W, Fu X, et al Inflammation and sarcopenia: A focus on circulating inflammatory cytokines. Exp Gerontol. 2021;154:111544. doi: 10.1016/j.exger.2021.111544. doi: 10.1016/j.exger.2021.111544. [DOI] [PubMed] [Google Scholar]
  • 48.Baar MP, Perdiguero E, Muñoz-Cánoves P, et al Musculoskeletal senescence: a moving target ready to be eliminated. Curr Opin Pharmacol. 2018;40:147–155. doi: 10.1016/j.coph.2018.05.007. [DOI] [PubMed] [Google Scholar]
  • 49.Xu J, She G, Gui T, et al Knee muscle atrophy is a risk factor for development of knee osteoarthritis in a rat model. J Orthop Translat. 2019;22:67–72. doi: 10.1016/j.jot.2019.10.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Tanaka R, Hirohama K, Ozawa J Can muscle weakness and disability influence the relationship between pain catastrophizing and pain worsening in patients with knee osteoarthritis? A cross-sectional study. Braz J Phys Ther. 2019;23(3):266–272. doi: 10.1016/j.bjpt.2018.08.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Steidle-Kloc E, Rabe K, Eckstein F, et al Is muscle strength in a painful limb affected by knee pain status of the contralateral limb? -Data from the Osteoarthritis Initiative. Ann Anat. 2019;221:68–75. doi: 10.1016/j.aanat.2018.08.003. [DOI] [PubMed] [Google Scholar]
  • 52.Noehren B, Kosmac K, Walton RG, et al Alterations in quadriceps muscle cellular and molecular properties in adults with moderate knee osteoarthritis. Osteoarthritis Cartilage. 2018;26(10):1359–1368. doi: 10.1016/j.joca.2018.05.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Silva JMS, Alabarse PVG, Teixeira VON, et al Muscle wasting in osteoarthritis model induced by anterior cruciate ligament transection. PLoS One. 2018;13(4):e0196682. doi: 10.1371/journal.pone.0196682. doi: 10.1371/journal.pone.0196682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Cunha JE, Barbosa GM, Castro PATS, et al Knee osteoarthritis induces atrophy and neuromuscular junction remodeling in the quadriceps and tibialis anterior muscles of rats. Sci Rep. 2019;9(1):6366. doi: 10.1038/s41598-019-42546-7. doi: 10.1038/s41598-019-42546-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Egloff C, Hart DA, Hewitt C, et al Joint instability leads to long-term alterations to knee synovium and osteoarthritis in a rabbit model. Osteoarthritis Cartilage. 2016;24(6):1054–1060. doi: 10.1016/j.joca.2016.01.341. [DOI] [PubMed] [Google Scholar]
  • 56.Chang JS, Kim TH, Nguyen TT, et al Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study. Geriatr Gerontol Int. 2017;17(11):2266–2273. doi: 10.1111/ggi.13030. [DOI] [PubMed] [Google Scholar]
  • 57.Mao Y, Xu W, Xie Z, et al Association of irisin and CRP levels with the radiographic severity of knee osteoarthritis. Genet Test Mol Biomarkers. 2016;20(2):86–89. doi: 10.1089/gtmb.2015.0170. [DOI] [PubMed] [Google Scholar]
  • 58.Li X, Zhu X, Wu H, et al Roles and mechanisms of irisin in attenuating pathological features of osteoarthritis. Front Cell Dev Biol. 2021;9:703670. doi: 10.3389/fcell.2021.703670. doi: 10.3389/fcell.2021.703670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Vadalà G, Di Giacomo G, Ambrosio L, et al Irisin recovers osteoarthritic chondrocytes in vitro. Cells. 2020;9(6):1478. doi: 10.3390/cells9061478. doi: 10.3390/cells9061478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Colaianni G, Cinti S, Colucci S, et al Irisin and musculoskeletal health. Ann N Y Acad Sci. 2017;1402(1):5–9. doi: 10.1111/nyas.13345. [DOI] [PubMed] [Google Scholar]
  • 61.Zhou K, Qiao X, Cai Y, et al Lower circulating irisin in middle-aged and older adults with osteoporosis: a systematic review and meta-analysis. Menopause. 2019;26(11):1302–1310. doi: 10.1097/GME.0000000000001388. [DOI] [PubMed] [Google Scholar]
  • 62.Liao CD, Liao YH, Liou TH, et al Effects of protein-rich nutritional composition supplementation on sarcopenia indices and physical activity during resistance exercise training in older women with knee osteoarthritis. Nutrients. 2021;13(8):2487. doi: 10.3390/nu13082487. doi: 10.3390/nu13082487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Vodička T, Bozděch M, Gimunová M, et al Could the evaluation of muscle strength imbalances be used as a predictor of total hip arthroplasty? Int J Environ Res Public Health. 2021;18(10):5082. doi: 10.3390/ijerph18105082. doi: 10.3390/ijerph18105082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Toda Y, Segal N, Kato A, et al Correlation between body composition and efficacy of lateral wedged insoles for medial compartment osteoarthritis of the knee. J Rheumatology. 2002;29(3):541–545. [PubMed] [Google Scholar]
  • 65.Wang XF, Ma ZH, Teng XR Isokinetic strength test of muscle strength and motor function in total knee arthroplasty. Orthop Surg. 2020;12(3):878–889. doi: 10.1111/os.12699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Cavanellas NT, Cossich VRA, Nicoliche EB, et al Comparative analysis of quadriceps and hamstrings strength in knee osteoarthritis before and after total knee arthroplasty: a cross-sectional study. Rev Bras Ortop. 2018;53(2):158–164. doi: 10.1016/j.rbo.2017.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Park J, Bae J, Lee J Complex exercise improves anti-inflammatory and anabolic effects in osteoarthritis-induced sarcopenia in elderly women. Healthcare (Basel) 2021;9(6):711. doi: 10.3390/healthcare9060711. doi: 10.3390/healthcare9060711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Ardeljan AD, Polisetty TS, Palmer J, et al Comparative analysis on the effects of sarcopenia following primary total knee arthroplasty: A retrospective matched-control analysis. J Knee Surg. 2022;35(2):128–134. doi: 10.1055/s-0040-1713355. [DOI] [PubMed] [Google Scholar]
  • 69.Liao CD, Chen HC, Huang SW, et al. Impact of sarcopenia on rehabilitation outcomes after total knee replacement in older adults with knee osteoarthritis. Ther Adv Musculoskelet Dis, 2021, 13: 1759720X21998508. doi: 10.1177/1759720X21998508.
  • 70.Babu JM, Kalagara S, Durand W, et al Sarcopenia as a risk factor for prosthetic infection after total hip or knee arthroplasty. J Arthroplasty. 2019;34(1):116–122. doi: 10.1016/j.arth.2018.09.037. [DOI] [PubMed] [Google Scholar]
  • 71.Mau-Moeller A, Behrens M, Felser S, et al Modulation and predictors of periprosthetic bone mineral density following total knee arthroplasty. Biomed Res Int. 2015;2015:418168. doi: 10.1155/2015/418168. doi: 10.1155/2015/418168. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Chinese Journal of Reparative and Reconstructive Surgery are provided here courtesy of Sichuan University

RESOURCES